Statin-induced myopathy in the rat: Relationship between systemic exposure, muscle exposure and myopathy

Xenobiotica

Volumn 39, Issue 1, 2009, Pages 90-98

  Sidaway, J ^a   Wang, Y ^a   Marsden, A M ^a   Orton, T C ^a   Westwood, F R ^a   Azuma, C T ^a   Scott, R C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase; Myopathy; Skeletal muscle; Statin

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; LIVER; MUSCLE CELL; MUSCLE INJURY; MUSCLE NECROSIS; MYOPATHY; NONHUMAN; RAT; SKELETAL MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MUSCLE, SKELETAL; MUSCULAR DISEASES; PYRIDINES; PYRIMIDINES; RATS; RATS, WISTAR; SIMVASTATIN; SULFONAMIDES;

RATTUS;

EID: 61649105525     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802585539     Document Type: Article

References (47)

1. Baker SK. 2005. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle and Nerve 31(5):572-580.
2. Bischoff H, Angerbauer R, Boberg M, Schmidt D. 1997. Cerivastatin high enzyme affinity and active metabolites contribute to its high pharmacological activity. Atherosclerosis 130(Suppl.):S25.
3. Boberg M, Angerbauer R, Kanhai WK, Karl W, Kern A, Radtke M, Steinke W. 1998. Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metabolism and Disposition 26(7):640-652.
4. Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, Fumagalli R, Paoletti R, Soma VM. 1996. Non-lipid-related effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Cardiology 87(6):458-468.
5. Farmer JA, Torre-Amione G. 2000. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Safety 23(3):197-213.
6. Flint OP, Masters BA, Gregg RE, Durham SK. 1997. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicology and Applied Pharmacology 145(1):99-110.
7. Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T, Tsujita Y. 1993. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Research in Experimental Medicine (Berlin) 193(5):263-273.
8. Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, Alberts AW. 1989. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochemical and Biophysical Research Communications 158(3):667-675.
9. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, Bokelman DL. 1989. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. American Journal of Medicine 87(4A):28S-38S.
10. Goldstein JL, Brown MS. 1990. Regulation of the mevalonate pathway. Nature 343(6257):425-430.
11. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. 2004. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. Journal of the American Medical Association 292(21):2585-2590.
12. Hodel C. 2002. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicology Letters 128(1-3):159-168.
13. Hrab RV, Hartman HA, Cox RH, Jr. 1994. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology 50(1):19-26.
14. Home Office. 1986. Guidance on the Operations of the Animals (Scientific Procedures) Act 1986. London: HMSO.
15. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, Umbenhauer DR. 2004. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicology and Applied Pharmacology 200(3):237-250.
16. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. 2003. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). American Journal of Cardiology 92(2):152-160.
17. Kobayashi M, Otsuka Y, Itagaki S, Hirano T, Iseki K. 2006. Inhibitory effects of statins on human monocarboxylate transporter 4. International Journal of Pharmaceutics 317(1):19-25.
18. Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y. 1992. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. European Journal of Biochemistry 209(1):315-319.
19. Lilja JJ, Kivisto KT, Neuvonen PJ. 1998. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clinical Pharmacology and Therapy 64(5):477-483.
20. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW, Bokelman DL. 1988. Preclinical evaluation of lovastatin. American Journal of Cardiology 62(15):16J-27J.
21. Madsen CS, Janovitz E, Zhang R, Nguyen-Tran V, Ryan CS, Yin X, Monshizadegan H, Chang M, D'Arienzo C, Scheer S, Setters R, Search D, Chen X, Zhuang S, Kunselman L, Peters A, Harrity T, Apedo A, Huang C, Cuff CA, Kowala MC, Blanar MA, Sun CQ, Robl JA, Stein PD. 2008. The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins. Journal of Pharmacology and Experimental Therapy 324(2):576-586.
22. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C, Scottolini AG. 1990. Rhabdomyolysis secondary to lovastatin therapy. Clinical Chemistry 36(12):2145-2147.
23. Matsuyama K, Nakagawa K, Nakai A, Konishi Y, Nishikata M, Tanaka H, Uchida T. 2002. Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method. Marine Biology and Pharmacology Bulletin 25(3):346-350.
24. McTaggart F. 2003. Comparative pharmacology of rosuvastatin. Atherosclerosis Suppl. 4(1):9-14.
25. Nakahara K, Kuriyama M, Yoshidome H, Nagata K, Nagado T, Nakagawa M, Arimura K, Higuchi I, Osame M. 1992. Experimental simvastatin-induced myopathy in rabbits. Journal of Neurology Science 113(1):114-117.
26. Neuvonen PJ, Niemi M, Backman JT. 2006. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical Pharmacology and Therapy 80(6):565-581.
27. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. 2006. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Journal of the American Medical Association 295(13):1556-1565.
28. Omar MA, Wilson JP, Cox TS. 2001. Rhabdomyolysis and HMG-CoA reductase inhibitors. Annals of Pharmacotherapy 35(9):1096-1107.
29. Pasternak RC, Smith SC, Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106(8):1024-1028.
30. Pierno S, De Luca A, Tricarico D, Roselli A, Natuzzi F, Ferrannini E, Laico M, Camerino DC. 1995. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. Journal of Pharmacology and Experimental Therapy 275(3):1490-1496.
31. Pierno S, Didonna MP, Cippone V, De Luca A, Pisoni M, Frigeri A, Nicchia GP, Svelto M, Chiesa G, Sirtori C, Scanziani E, Rizzo C, De Vito D, Conte Camerino D. 2006. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. British Journal of Pharmacology 149(7):909-919.
32. Ravnan SL, Locke C, Yee WP, Haase K. 2002. Cerivastatin-induced rhabdomyolysis: 11 case reports. Pharmacotherapy 22(4):533-537.
33. Rosenson RS. 2004. Current overview of statin-induced myopathy. American Journal of Medicine 116(6):408-416.
34. Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J. 2007. Rab-small GTPases are involved in fluvastatin and pravastatininduced vacuolation in rat skeletal myofibers. FASEB Journal 21(14):4087-4094.
35. Sakamoto K, Mikami H, Kimura J. 2008. Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres. British Journal of Pharmacology 154:1482-1490.
36. Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC, Raab CE, Yu NX, Lankas GR, Frederick CB. 2004. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicology and Applied Pharmacology 194(1):10-23.
37. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clinical Pharmacology and Therapy 75(5):455-463.
38. Seachrist JL, Loi CM, Evans MG, Criswell KA, Rothwell CE. 2005. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicology Science 88(2):551-561.
39. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas KP, Kari PH, MacDonald JS. 1991. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. Journal of Pharmacology and Experimental Therapy 257(3):1225-1235.
40. Staffa JA, Chang J, Green L. 2002. Cerivastatin and reports of fatal rhabdomyolysis. New England Journal of Medicine 346(7):539-540.
41. Takeda M, Noshiro R, Onozato ML, Tojo A, Hasannejad H, Huang XL, Narikawa S, Endou H. 2004. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. European Journal of Pharmacology 483(2-3):133-138.
42. The SEARCH Collaborative Group. 2008. SLCO1B1 variants and statin-induced myopathy - a genomewide study. New England Journal of Medicine 359:789-799.
43. Tobert JA. 2003. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews in Drug Discovery 2(7):517-526.
44. Waclawik AJ, Lindal S, Engel AG. 1993. Experimental lovastatin myopathy. Journal of Neuropathology and Experimental Neurology 52(5):542-549.
45. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. 2005. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicology and Pathology 33(2):246-257.
46. Westwood FR, Scott RC, Marsden AM, Bigley A, Randall K. 2008. Rosuvastatin: characterization of induced myopathy in the rat. Toxicology and Pathology 36(2):345-352.
47. Yamazaki H, Suzuki M, Aoki T, Morikawa S, Maejima T, Sato F, Sawanobori K, Kitahara M, Kodama T, Saito Y. 2006. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ubiquinone levels in rat skeletal muscle and heart: relationship to cytotoxicity and inhibitory activity for cholesterol synthesis in human skeletal muscle cells. Journal of Atherosclerosis and Thrombosis 13(6):295-307.